VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study

Abstract

BackgroundIn advanced age the prognosis of Hodgkin’s lymphoma (HL) is poor, but, as a consequence of the low incidence of HL in the elderly, prospective studies are lacking and the best treatment strategy is difficult to define. Patients and methodsOne-hundred and five HL patients over 65 years of age were treated homogeneously with an original reduced-intensity regimen designed for HL in the elderly containing vinblastine, cyclophosphamide, procarbazine, etoposide, mitoxantrone and bleomycin (VEPEMB). Forty-eight early stage (IA–IIA) patients received three courses of VEPEMB followed by involved field irradiation. Fifty-seven advanced stage (IIB–IV) patients received six courses followed by radiotherapy limited to the areas of bulky disease. ResultsMean age was 71 years (range 66–83). Co-morbidities were present in 39 patients (37%). A treatment plan modification for poor tolerance or toxicity was needed in 18 patients. Results were satisfactory, even ifthey were better in early rather than in advanced stage disease: complete response rate 98% versus 58%(P <0.01); 5-year failure-free survival 79% versus 34% (P <0.01). The results were affected by advanced stage, systemic symptoms and co-morbidity but they were not influenced by age itself. ConclusionsVEPEMB is an effective and low toxic regimen for HL in the elderly. Co-morbidity is a prognostic factor more important than age itself.